{"gene":"TK2","run_date":"2026-04-28T21:42:59","timeline":{"discoveries":[{"year":2002,"finding":"Human TK2 (and Xenopus orthologue Xen-PyK) phosphorylates pyrimidine deoxynucleosides (thymidine and deoxycytidine) following Michaelis-Menten kinetics for deoxycytidine and showing negative cooperativity with thymidine; TK2-like enzymes exist as homodimers and are subject to feedback inhibition by dTTP and dCTP in a complex substrate-dependent pattern, distinguishing them from other deoxyribonucleoside kinase subfamilies.","method":"In vitro enzyme kinetics, substrate specificity assays, analytical ultracentrifugation (homodimer determination), feedback inhibition assays with purified recombinant enzymes","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro enzyme kinetics with multiple orthogonal biochemical methods","pmids":["11812127"],"is_preprint":false},{"year":2003,"finding":"TK2 deficiency causes mtDNA depletion and respiratory chain dysfunction selectively in skeletal muscle because this tissue combines low basal TK2 activity with a high requirement for mitochondrially encoded proteins; other tissues (liver, brain, heart, skin) maintain normal mtDNA content and remain unaffected.","method":"TK2 enzyme activity assays and mtDNA content measurement in mitochondria isolated from multiple tissues of TK2-deficient patients","journal":"Molecular genetics and metabolism","confidence":"High","confidence_rationale":"Tier 2 — direct biochemical measurement across multiple tissues establishing mechanistic basis of tissue specificity","pmids":["12765840"],"is_preprint":false},{"year":2003,"finding":"Non-nucleoside tritylated compounds (e.g., KIN-52) are the first selective non-nucleoside inhibitors of TK2, acting as reversible, purely uncompetitive inhibitors with respect to ATP (contrasting with BVDU which is noncompetitive), and competitively with respect to thymidine, without being alternative substrates; molecular modeling places them outside the nucleoside binding pocket.","method":"Enzyme inhibition kinetics (IC50, Ki determination), competitive inhibition analysis with respect to thymidine and ATP, computer-assisted molecular modeling","journal":"Molecular pharmacology","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinetic characterization with mechanistic inhibition analysis and molecular modeling","pmids":["12527796"],"is_preprint":false},{"year":2007,"finding":"Transgenic cardiac overexpression of TK2 (but not cytosolic TK1) in mice doubles mtDNA abundance, increases complex I subunit levels, succinate dehydrogenase activity, and cristae density, demonstrating that TK2 activity is rate-limiting for mitochondrial dNTP supply and mtDNA biogenesis in heart; NRTI treatment abrogates the functional effects of elevated TK2 activity, linking TK2-mediated mitochondrial phosphorylation to NRTI mitochondrial toxicity.","method":"Cardiac-specific transgenic mouse overexpression, echocardiography, NMR imaging, TK enzyme activity assays, mtDNA quantification, immunohistochemistry, electron microscopy","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — in vivo transgenic gain-of-function with multiple orthogonal readouts establishing causal role of TK2 in mtDNA maintenance","pmids":["17322372"],"is_preprint":false},{"year":2008,"finding":"FMAU (fluoroarabinofuranosyl thymine) is preferentially phosphorylated by mitochondrial TK2 rather than cytosolic TK1; TK2 inhibition selectively decreases FMAU retention and phosphorylation; FMAU retention correlates with TK2 activity and mitochondrial mass under cellular stress conditions (r²=0.87–0.88), establishing TK2 as the primary kinase for FMAU in mitochondria.","method":"Radiotracer retention assays, HPLC metabolite analysis, TK1/TK2 activity assays (FLT/Ara-T phosphorylation), flow cytometry for mitochondrial mass, selective TK2 inhibition","journal":"European journal of nuclear medicine and molecular imaging","confidence":"High","confidence_rationale":"Tier 1–2 — direct enzyme activity assays, selective inhibition, and multiple correlative methods in cell lines","pmids":["18265975"],"is_preprint":false},{"year":2009,"finding":"In TK2-deficient fibroblasts, upregulation of the human equilibrative nucleoside transporter 1 (hENT1) at both mRNA and protein levels serves as a compensatory mechanism maintaining normal mtDNA levels; siRNA knockdown of hENT1 (but not TK1) induces mtDNA depletion in TK2-deficient cells, establishing hENT1 as a functional bypass for TK2 in mtDNA maintenance.","method":"Real-time RT-PCR, western blotting, siRNA knockdown, mtDNA quantification by real-time PCR in patient-derived fibroblasts","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 2 — siRNA epistasis experiment with defined molecular phenotype (mtDNA depletion) in patient-derived cells","pmids":["19265691"],"is_preprint":false},{"year":2010,"finding":"Disease onset and organ specificity in TK2 deficiency are determined by the developmental downregulation of cytosolic TK1: Tk2-knockout mice are normal until postnatal day 8 when Tk1 activity decreases, unmasking Tk2 deficiency and triggering mtDNA depletion in brain and heart. Tk2-deficient heart compensates by downregulating mitochondrial transcription terminator MTERF3 to increase mitochondrial transcript levels relative to mtDNA, maintaining normal mtDNA-encoded protein levels.","method":"Tk2 H126N knockin mouse model (Tk2-/-), TK enzyme activity assays across developmental time points, mtDNA quantification, RT-PCR for mitochondrial transcripts and biogenesis regulators, protein quantification","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic knockin mouse model with mechanistic dissection of onset and organ specificity across multiple tissues and timepoints","pmids":["20940150"],"is_preprint":false},{"year":2015,"finding":"TK2 phosphorylates deoxycytidine to generate dCTP; siRNA knockdown of TK2 in cancer cells reduces dCTP levels, increases deoxycytidine kinase (dCK) activity, and sensitizes high-TK2-expressing tumor cells (MCF7, HeLa) to gemcitabine by enhancing gemcitabine activation and causing mitochondrial damage (decreased mitochondrial redox status, DNA content, and respiratory activity); knockdown of TK1 or thymidylate synthase does not replicate this effect.","method":"siRNA knockdown, cell viability assays, dCTP/dNTP pool measurement, dCK activity assay, mitochondrial function assays (redox status, mtDNA content, complex activity), comparative KD of TK1 and TS","journal":"Oncotarget","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with multiple orthogonal mechanistic readouts and genetic controls distinguishing TK2 from paralogs","pmids":["26087398"],"is_preprint":false},{"year":2019,"finding":"Therapeutic efficacy of deoxycytidine (dCtd) + thymidine (dThd) supplementation in Tk2-deficient mice depends critically on cytosolic pyrimidine salvage enzymes TK1 and dCK, which convert the exogenous deoxynucleosides to monophosphates; temporal and tissue-specific downregulation of TK1 correlates with the onset and organ specificity of disease and with tissue-specific therapeutic response. In human muscle, expression of both TK1 and dCK accounts for long-term therapeutic efficacy of deoxynucleoside therapy.","method":"Tk2-/- knockin mouse model, parenteral vs. oral deoxynucleoside dosing, tissue deoxynucleoside bioavailability measurement, TK1/dCK enzyme activity assays, mtDNA quantification across tissues, human muscle expression analysis","journal":"EBioMedicine","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection in mouse model with human tissue validation and multiple orthogonal readouts","pmids":["31383553"],"is_preprint":false},{"year":2020,"finding":"In adult rat tissues, a cytosolic isoform of TK2 exists with similar substrate specificity to mitochondrial TK2; skeletal muscle mitochondria have the lowest total TK activity of all tissues examined, indicating they are most dependent on both the salvage and de novo synthesis pathways for dTTP, explaining why TK2 deficiency preferentially affects skeletal muscle.","method":"Enzyme activity assays in cytosolic and mitochondrial fractions from multiple rat tissues, substrate specificity characterization, thymidylate synthase and p53R2 protein/activity measurement","journal":"BMC molecular and cell biology","confidence":"Medium","confidence_rationale":"Tier 2 — direct biochemical characterization across tissues, single lab study","pmids":["32345222"],"is_preprint":false},{"year":2025,"finding":"TK2 and CMPK2 (cytidine/uridine monophosphate kinase 2) physically interact in the mitochondrial matrix, forming a functional complex that channels thymidine through two-step phosphorylation (thymidine → TMP → TDP) in a compartmentalized manner; TMP provided exogenously is dephosphorylated to thymidine before salvage by TK2, and this compartmentalization—not transport barriers—accounts for the inability of exogenous TMP to serve as a direct precursor for dTTP synthesis in intact or broken mitochondria from heart, liver, kidney, and brain.","method":"Isolated intact and broken mitochondria from rat heart, liver, kidney, and brain; azidothymidine (TK2 inhibitor) blocking experiments; radiolabeled TMP incorporation assays; proximity labeling; immunofluorescence microscopy; differential fractionation","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — reconstitution in isolated mitochondria with inhibitor controls, proximity labeling, and fractionation across multiple tissues","pmids":["40967432"],"is_preprint":false},{"year":2026,"finding":"Loss of TK2 in brain tissue activates the cGAS-STING innate immune pathway, upregulates inflammatory genes, and increases seizure susceptibility; TK2 expression is inversely correlated with seizure frequency in human epileptogenic brain tissue and is reduced in multiple brain regions in two rodent seizure models, establishing a mechanistic link between TK2-mediated mitochondrial function, mitochondrial DNA-driven inflammation, and neuronal excitability.","method":"Proteomic profiling of human epileptogenic brain tissue, pilocarpine and ferric chloride rodent seizure models, Tk2 knockdown/loss-of-function, cGAS-STING pathway gene expression analysis, seizure susceptibility assays","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with pathway-level mechanistic follow-up (cGAS-STING), single lab, human tissue correlation","pmids":["41500441"],"is_preprint":false},{"year":2006,"finding":"N1-substituted thymine derivatives with a hexamethylene spacer competitively inhibit TK2 with respect to thymidine and uncompetitively with respect to ATP (IC50 0.3–0.5 µM), as modeled by docking into a homology-based structure of human TK2, identifying structural determinants of TK2 active site selectivity.","method":"Enzyme inhibition kinetics, IC50 determination against TK2/Dm-dNK/HSV-1 TK, competitive inhibition analysis, homology modeling and docking","journal":"Journal of medicinal chemistry","confidence":"Medium","confidence_rationale":"Tier 1–2 — in vitro enzyme kinetics with mechanistic inhibition mode determination and structural modeling; single lab","pmids":["17181158"],"is_preprint":false}],"current_model":"TK2 is a mitochondrial matrix pyrimidine deoxynucleoside kinase (homodimer) that phosphorylates thymidine and deoxycytidine as the rate-limiting step in the mitochondrial salvage pathway for dNTP supply; its activity is essential for mtDNA maintenance in post-mitotic tissues (especially skeletal muscle, which has the lowest compensatory TK capacity), disease onset in TK2-deficient mice is triggered by developmental downregulation of cytosolic TK1, TK2 physically associates with CMPK2 in the mitochondrial matrix to channel thymidine through compartmentalized two-step phosphorylation, loss of TK2 activates the cGAS-STING inflammatory pathway, and cytosolic salvage enzymes TK1 and dCK are critical determinants of the therapeutic efficacy of deoxynucleoside substrate supplementation."},"narrative":{"teleology":[{"year":2002,"claim":"Establishing TK2's fundamental enzymology—homodimeric architecture, dual pyrimidine substrate specificity, and product feedback inhibition—defined it as a distinct deoxynucleoside kinase subfamily with a unique regulatory logic.","evidence":"Purified recombinant enzyme kinetics, analytical ultracentrifugation, and feedback inhibition assays","pmids":["11812127"],"confidence":"High","gaps":["No crystal structure of human TK2 was solved","Kinetic parameters under physiological dNTP concentrations were not measured","Regulation by post-translational modifications unknown"]},{"year":2003,"claim":"Measurement of TK2 activity across patient tissues revealed that skeletal muscle uniquely combines low basal TK2 activity with high mitochondrial protein demand, explaining the tissue-selective mtDNA depletion in TK2 deficiency.","evidence":"TK2 enzyme activity assays and mtDNA quantification in mitochondria from multiple tissues of TK2-deficient patients","pmids":["12765840"],"confidence":"High","gaps":["Brain involvement was not fully characterized at this stage","Developmental timing of disease onset not yet explained"]},{"year":2003,"claim":"Identification of non-nucleoside uncompetitive TK2 inhibitors demonstrated that the enzyme's active site accommodates non-substrate ligands at a distinct binding mode, opening pharmacological dissection of TK2 function.","evidence":"In vitro enzyme inhibition kinetics and molecular modeling with tritylated compounds","pmids":["12527796"],"confidence":"High","gaps":["No cellular or in vivo validation of inhibitors","Binding site not experimentally resolved"]},{"year":2007,"claim":"Cardiac-specific TK2 overexpression doubled mtDNA abundance and increased respiratory complex levels, proving TK2 is rate-limiting for mitochondrial dNTP supply and mtDNA biogenesis in vivo, and linking TK2-mediated phosphorylation to NRTI mitochondrial toxicity.","evidence":"Transgenic mouse overexpression with echocardiography, NMR, mtDNA quantification, and electron microscopy","pmids":["17322372"],"confidence":"High","gaps":["Whether rate-limiting role generalizes to all post-mitotic tissues was untested","Mechanism of NRTI interaction with TK2 substrates not fully dissected"]},{"year":2009,"claim":"Discovery that hENT1 upregulation compensates for TK2 loss in fibroblasts—and that hENT1 knockdown unmasks mtDNA depletion—identified nucleoside transport as a bypass route, explaining why some cell types tolerate TK2 deficiency.","evidence":"siRNA knockdown of hENT1 and TK1 in patient-derived TK2-deficient fibroblasts with mtDNA quantification","pmids":["19265691"],"confidence":"High","gaps":["Whether hENT1 compensation operates in affected tissues (muscle, brain) in vivo was unknown","Mechanism linking enhanced transport to dNTP synthesis unclear"]},{"year":2010,"claim":"The Tk2 knockin mouse revealed that disease onset at postnatal day 8 is triggered by developmental downregulation of cytosolic TK1, establishing that the timing and organ specificity of TK2-deficiency disease reflect the balance between mitochondrial and cytosolic salvage pathways.","evidence":"Tk2 H126N knockin mouse with TK activity assays across developmental timepoints and tissues, mtDNA and transcript quantification","pmids":["20940150"],"confidence":"High","gaps":["Signals controlling developmental TK1 downregulation not identified","Compensatory MTERF3 mechanism in heart not tested by genetic rescue"]},{"year":2019,"claim":"Demonstrating that therapeutic deoxynucleoside supplementation depends on cytosolic TK1 and dCK for substrate activation explained tissue-specific therapeutic efficacy and established the pharmacological bottleneck for TK2-deficiency treatment.","evidence":"Tk2-/- mouse model with parenteral and oral deoxynucleoside dosing, tissue bioavailability, enzyme activity assays, and human muscle expression validation","pmids":["31383553"],"confidence":"High","gaps":["Optimal dosing regimen and long-term efficacy in patients not established mechanistically","Whether direct mitochondrial nucleotide delivery could bypass cytosolic activation untested"]},{"year":2020,"claim":"Detection of a cytosolic TK2 isoform in rat tissues and confirmation that skeletal muscle mitochondria have the lowest total TK capacity of any tissue reinforced the mechanistic basis for muscle-selective vulnerability.","evidence":"Enzyme activity assays in cytosolic and mitochondrial fractions from multiple rat tissues","pmids":["32345222"],"confidence":"Medium","gaps":["Cytosolic TK2 isoform not characterized at the molecular level (alternative splicing, protein identity)","Findings from rat tissue not validated in human samples"]},{"year":2025,"claim":"Discovery that TK2 physically associates with CMPK2 in the mitochondrial matrix to channel thymidine through compartmentalized two-step phosphorylation resolved why exogenous TMP cannot serve as a direct dTTP precursor—it must be dephosphorylated and re-phosphorylated by the TK2-CMPK2 complex.","evidence":"Isolated intact and broken mitochondria from multiple rat tissues, azidothymidine blocking, radiolabeled TMP assays, proximity labeling, immunofluorescence","pmids":["40967432"],"confidence":"High","gaps":["Stoichiometry and structural basis of TK2-CMPK2 complex not determined","Whether the complex includes additional partners (e.g., NDPK) unknown","Functional significance in human tissues not directly tested"]},{"year":2026,"claim":"Linking TK2 loss in brain to cGAS-STING pathway activation and increased seizure susceptibility established a previously unrecognized connection between mitochondrial dNTP salvage, mtDNA-driven innate immunity, and neuronal excitability.","evidence":"Proteomic profiling of human epileptogenic brain, rodent seizure models, Tk2 knockdown, cGAS-STING gene expression analysis","pmids":["41500441"],"confidence":"Medium","gaps":["Whether cGAS-STING activation is caused by mtDNA release or nuclear DNA damage not distinguished","Causal chain from TK2 loss to seizure phenotype not fully delineated","Single-lab finding awaiting independent replication"]},{"year":null,"claim":"A high-resolution structure of the human TK2-CMPK2 complex, the identity and regulation of the putative cytosolic TK2 isoform, and the precise mechanism by which TK2 deficiency triggers cGAS-STING activation remain unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No crystal or cryo-EM structure of human TK2 or TK2-CMPK2 complex","Molecular identity of cytosolic TK2 isoform undetermined","Specific mtDNA species or damage signals activating cGAS-STING downstream of TK2 loss not identified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,3,4,7]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[1,3,10]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,3,7,10]},{"term_id":"R-HSA-69306","term_label":"DNA Replication","supporting_discovery_ids":[3,6]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[11]}],"complexes":["TK2-CMPK2 mitochondrial matrix complex"],"partners":["CMPK2","SLC29A1"],"other_free_text":[]},"mechanistic_narrative":"TK2 is a mitochondrial matrix pyrimidine deoxynucleoside kinase that catalyzes the rate-limiting phosphorylation of thymidine and deoxycytidine in the mitochondrial salvage pathway, thereby sustaining dNTP pools essential for mtDNA replication and maintenance in post-mitotic tissues. TK2 functions as a homodimer subject to feedback inhibition by dTTP and dCTP, displays negative cooperativity with thymidine, and physically associates with CMPK2 in the mitochondrial matrix to channel thymidine through compartmentalized two-step phosphorylation to TDP [PMID:11812127, PMID:40967432]. Tissue-specific vulnerability to TK2 deficiency—most severe in skeletal muscle and brain—is determined by the developmental downregulation of cytosolic TK1, which unmasks the dependence on mitochondrial salvage; compensatory mechanisms including hENT1 upregulation can partially buffer mtDNA depletion in some cell types [PMID:20940150, PMID:12765840, PMID:19265691]. Loss of TK2 in brain activates the cGAS-STING innate immune pathway and increases seizure susceptibility, while therapeutic deoxynucleoside supplementation in TK2 deficiency requires cytosolic TK1 and dCK for conversion of exogenous substrates [PMID:41500441, PMID:31383553]."},"prefetch_data":{"uniprot":{"accession":"O00142","full_name":"Thymidine kinase 2, mitochondrial","aliases":["2'-deoxyuridine kinase TK2","Deoxycytidine kinase TK2","Mt-TK"],"length_aa":265,"mass_kda":31.0,"function":"Phosphorylates thymidine, deoxycytidine, and deoxyuridine in the mitochondrial matrix (PubMed:11687801, PubMed:9989599). In non-replicating cells, where cytosolic dNTP synthesis is down-regulated, mtDNA synthesis depends solely on TK2 and DGUOK (PubMed:9989599). Widely used as target of antiviral and chemotherapeutic agents (PubMed:9989599)","subcellular_location":"Mitochondrion","url":"https://www.uniprot.org/uniprotkb/O00142/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TK2","classification":"Not Classified","n_dependent_lines":36,"n_total_lines":1208,"dependency_fraction":0.029801324503311258},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TK2","total_profiled":1310},"omim":[{"mim_id":"617069","title":"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA WITH MITOCHONDRIAL DNA DELETIONS, AUTOSOMAL RECESSIVE 3; PEOB3","url":"https://www.omim.org/entry/617069"},{"mim_id":"612051","title":"BRAIN-EXPRESSED, ASSOCIATED WITH NEDD4, 1; BEAN1","url":"https://www.omim.org/entry/612051"},{"mim_id":"611787","title":"CYTIDINE MONOPHOSPHATE (UMP-CMP) KINASE 2, MITOCHONDRIAL; CMPK2","url":"https://www.omim.org/entry/611787"},{"mim_id":"609560","title":"MITOCHONDRIAL DNA DEPLETION SYNDROME 2 (MYOPATHIC TYPE); MTDPS2","url":"https://www.omim.org/entry/609560"},{"mim_id":"603041","title":"MITOCHONDRIAL DNA DEPLETION SYNDROME 1 (MNGIE TYPE); MTDPS1","url":"https://www.omim.org/entry/603041"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TK2"},"hgnc":{"alias_symbol":["SCA31"],"prev_symbol":[]},"alphafold":{"accession":"O00142","domains":[{"cath_id":"3.40.50.300","chopping":"52-257","consensus_level":"medium","plddt":96.0153,"start":52,"end":257}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00142","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00142-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00142-F1-predicted_aligned_error_v6.png","plddt_mean":84.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TK2","jax_strain_url":"https://www.jax.org/strain/search?query=TK2"},"sequence":{"accession":"O00142","fasta_url":"https://rest.uniprot.org/uniprotkb/O00142.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00142/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00142"}},"corpus_meta":[{"pmid":"24484525","id":"PMC_24484525","title":"Transcriptomic profiling of TK2 deficient human skeletal muscle suggests a role for the p53 signalling pathway and identifies growth and differentiation factor-15 as a potential novel biomarker for mitochondrial myopathies.","date":"2014","source":"BMC genomics","url":"https://pubmed.ncbi.nlm.nih.gov/24484525","citation_count":114,"is_preprint":false},{"pmid":"28343865","id":"PMC_28343865","title":"Regulatory Role of RNA Chaperone TDP-43 for RNA Misfolding and Repeat-Associated Translation in SCA31.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28343865","citation_count":101,"is_preprint":false},{"pmid":"12765840","id":"PMC_12765840","title":"mtDNA depletion myopathy: elucidation of the tissue specificity in the mitochondrial thymidine kinase (TK2) deficiency.","date":"2003","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/12765840","citation_count":87,"is_preprint":false},{"pmid":"16504786","id":"PMC_16504786","title":"New mutations in TK2 gene associated with mitochondrial DNA depletion.","date":"2006","source":"Pediatric neurology","url":"https://pubmed.ncbi.nlm.nih.gov/16504786","citation_count":53,"is_preprint":false},{"pmid":"12873860","id":"PMC_12873860","title":"Mitochondrial myopathy of childhood associated with mitochondrial DNA depletion and a homozygous mutation (T77M) in the TK2 gene.","date":"2003","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12873860","citation_count":51,"is_preprint":false},{"pmid":"12682338","id":"PMC_12682338","title":"Reversion of mtDNA depletion in a patient with TK2 deficiency.","date":"2003","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/12682338","citation_count":45,"is_preprint":false},{"pmid":"22345218","id":"PMC_22345218","title":"Adult cases of mitochondrial DNA depletion due to TK2 defect: an expanding spectrum.","date":"2012","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/22345218","citation_count":41,"is_preprint":false},{"pmid":"18508266","id":"PMC_18508266","title":"Novel mutations in the TK2 gene associated with fatal mitochondrial DNA depletion myopathy.","date":"2008","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/18508266","citation_count":39,"is_preprint":false},{"pmid":"11812127","id":"PMC_11812127","title":"Deoxyribonucleoside kinases belonging to the thymidine kinase 2 (TK2)-like group vary significantly in substrate specificity, kinetics and feed-back regulation.","date":"2002","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11812127","citation_count":35,"is_preprint":false},{"pmid":"23932787","id":"PMC_23932787","title":"Molecular and clinical characterization of the myopathic form of mitochondrial DNA depletion syndrome caused by mutations in the thymidine kinase (TK2) gene.","date":"2013","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/23932787","citation_count":34,"is_preprint":false},{"pmid":"32572108","id":"PMC_32572108","title":"Growth Differentiation Factor 15 is a potential biomarker of therapeutic response for TK2 deficient myopathy.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32572108","citation_count":31,"is_preprint":false},{"pmid":"18265975","id":"PMC_18265975","title":"Tracking cellular stress with labeled FMAU reflects changes in mitochondrial TK2.","date":"2008","source":"European journal of nuclear medicine and molecular imaging","url":"https://pubmed.ncbi.nlm.nih.gov/18265975","citation_count":31,"is_preprint":false},{"pmid":"20940150","id":"PMC_20940150","title":"Onset and organ specificity of Tk2 deficiency depends on Tk1 down-regulation and transcriptional compensation.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20940150","citation_count":29,"is_preprint":false},{"pmid":"23303857","id":"PMC_23303857","title":"TK2 mutation presenting as indolent myopathy.","date":"2013","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23303857","citation_count":26,"is_preprint":false},{"pmid":"15907288","id":"PMC_15907288","title":"Novel mutations in the thymidine kinase 2 gene (TK2) associated with fatal mitochondrial myopathy and mitochondrial DNA depletion.","date":"2005","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/15907288","citation_count":26,"is_preprint":false},{"pmid":"17322372","id":"PMC_17322372","title":"Targeted transgenic overexpression of mitochondrial thymidine kinase (TK2) alters mitochondrial DNA (mtDNA) and mitochondrial polypeptide abundance: transgenic TK2, mtDNA, and antiretrovirals.","date":"2007","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/17322372","citation_count":25,"is_preprint":false},{"pmid":"10478487","id":"PMC_10478487","title":"Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O'-alkyl analogues.","date":"1999","source":"Nucleosides & nucleotides","url":"https://pubmed.ncbi.nlm.nih.gov/10478487","citation_count":24,"is_preprint":false},{"pmid":"18459168","id":"PMC_18459168","title":"Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future.","date":"2008","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/18459168","citation_count":23,"is_preprint":false},{"pmid":"31755042","id":"PMC_31755042","title":"Molecular Mechanisms and Future Therapeutics for Spinocerebellar Ataxia Type 31 (SCA31).","date":"2019","source":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31755042","citation_count":21,"is_preprint":false},{"pmid":"24198295","id":"PMC_24198295","title":"Late-onset respiratory failure due to TK2 mutations causing multiple mtDNA deletions.","date":"2013","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24198295","citation_count":21,"is_preprint":false},{"pmid":"31383553","id":"PMC_31383553","title":"Bioavailability and cytosolic kinases modulate response to deoxynucleoside therapy in TK2 deficiency.","date":"2019","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/31383553","citation_count":19,"is_preprint":false},{"pmid":"12527796","id":"PMC_12527796","title":"Non-nucleoside inhibitors of mitochondrial thymidine kinase (TK-2) differentially inhibit the closely related herpes simplex virus type 1 TK and Drosophila melanogaster multifunctional deoxynucleoside kinase.","date":"2003","source":"Molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/12527796","citation_count":18,"is_preprint":false},{"pmid":"25446393","id":"PMC_25446393","title":"Clinical application of whole exome sequencing reveals a novel compound heterozygous TK2-mutation in two brothers with rapidly progressive combined muscle-brain atrophy, axonal neuropathy, and status epilepticus.","date":"2014","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/25446393","citation_count":17,"is_preprint":false},{"pmid":"20421844","id":"PMC_20421844","title":"Hearing loss in a patient with the myopathic form of mitochondrial DNA depletion syndrome and a novel mutation in the TK2 gene.","date":"2010","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/20421844","citation_count":17,"is_preprint":false},{"pmid":"18021809","id":"PMC_18021809","title":"Selective muscle fiber loss and molecular compensation in mitochondrial myopathy due to TK2 deficiency.","date":"2007","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/18021809","citation_count":16,"is_preprint":false},{"pmid":"19815440","id":"PMC_19815440","title":"Application of oligonucleotide array CGH to the simultaneous detection of a deletion in the nuclear TK2 gene and mtDNA depletion.","date":"2010","source":"Molecular genetics and metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/19815440","citation_count":14,"is_preprint":false},{"pmid":"24455740","id":"PMC_24455740","title":"DPYD, TYMS, TYMP, TK1, and TK2 genetic expressions as response markers in locally advanced rectal cancer patients treated with fluoropyrimidine-based chemoradiotherapy.","date":"2013","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24455740","citation_count":14,"is_preprint":false},{"pmid":"33649356","id":"PMC_33649356","title":"Complete genome sequencing of Bacillus sp. TK-2, analysis of its cold evolution adaptability.","date":"2021","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/33649356","citation_count":14,"is_preprint":false},{"pmid":"38544965","id":"PMC_38544965","title":"Clinical and Genetic Analysis of Patients With TK2 Deficiency.","date":"2024","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/38544965","citation_count":13,"is_preprint":false},{"pmid":"22571666","id":"PMC_22571666","title":"Recent advances in thymidine kinase 2 (TK2) inhibitors and new perspectives for potential applications.","date":"2012","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/22571666","citation_count":12,"is_preprint":false},{"pmid":"24953930","id":"PMC_24953930","title":"Mitochondrial DNA depletion in single fibers in a patient with novel TK2 mutations.","date":"2014","source":"Neuromuscular disorders : NMD","url":"https://pubmed.ncbi.nlm.nih.gov/24953930","citation_count":12,"is_preprint":false},{"pmid":"21163552","id":"PMC_21163552","title":"SCA31 is rare in the Chinese population on Taiwan.","date":"2010","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/21163552","citation_count":12,"is_preprint":false},{"pmid":"34113230","id":"PMC_34113230","title":"Insight Into Spinocerebellar Ataxia Type 31 (SCA31) From Drosophila Model.","date":"2021","source":"Frontiers in neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/34113230","citation_count":11,"is_preprint":false},{"pmid":"35286480","id":"PMC_35286480","title":"Muscle MRI characteristic pattern for late-onset TK2 deficiency diagnosis.","date":"2022","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35286480","citation_count":11,"is_preprint":false},{"pmid":"17181158","id":"PMC_17181158","title":"N1-substituted thymine derivatives as mitochondrial thymidine kinase (TK-2) inhibitors.","date":"2006","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17181158","citation_count":11,"is_preprint":false},{"pmid":"38599303","id":"PMC_38599303","title":"Remarkable clinical improvement with oral nucleoside treatment in a patient with adult-onset TK2 deficiency: A case report.","date":"2024","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/38599303","citation_count":10,"is_preprint":false},{"pmid":"26087398","id":"PMC_26087398","title":"siRNA knockdown of mitochondrial thymidine kinase 2 (TK2) sensitizes human tumor cells to gemcitabine.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26087398","citation_count":9,"is_preprint":false},{"pmid":"17065084","id":"PMC_17065084","title":"The role of mitochondrial dNTP levels in cells with reduced TK2 activity.","date":"2006","source":"Nucleosides, nucleotides & nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/17065084","citation_count":9,"is_preprint":false},{"pmid":"15351391","id":"PMC_15351391","title":"Synthesis and evaluation of thymine-derived carboxamides against mitochondrial thymidine kinase (TK-2) and related enzymes.","date":"2004","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15351391","citation_count":9,"is_preprint":false},{"pmid":"36319738","id":"PMC_36319738","title":"Spinocerebellar ataxia type 31 (SCA31).","date":"2022","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/36319738","citation_count":8,"is_preprint":false},{"pmid":"36374792","id":"PMC_36374792","title":"The impact of TK2 deficiency syndrome and its treatment by nucleoside therapy on quality of life.","date":"2022","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/36374792","citation_count":8,"is_preprint":false},{"pmid":"19265691","id":"PMC_19265691","title":"Altered gene transcription profiles in fibroblasts harboring either TK2 or DGUOK mutations indicate compensatory mechanisms.","date":"2009","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19265691","citation_count":8,"is_preprint":false},{"pmid":"34070501","id":"PMC_34070501","title":"Preferent Diaphragmatic Involvement in TK2 Deficiency: An Autopsy Case Study.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34070501","citation_count":8,"is_preprint":false},{"pmid":"18600552","id":"PMC_18600552","title":"5-Bromovinyl 2'-deoxyuridine phosphorylation by mitochondrial and cytosolic thymidine kinase (TK2 and TK1) and its use in selective measurement of TK2 activity in crude extracts.","date":"2008","source":"Nucleosides, nucleotides & nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/18600552","citation_count":8,"is_preprint":false},{"pmid":"21267591","id":"PMC_21267591","title":"Two dominantly inherited ataxias linked to chromosome 16q22.1: SCA4 and SCA31 are not allelic.","date":"2011","source":"Journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21267591","citation_count":7,"is_preprint":false},{"pmid":"24990830","id":"PMC_24990830","title":"[Clinical features and MRI findings in spinocerebellar ataxia type 31 (SCA31) comparing with spinocerebellar ataxia type 6 (SCA6)].","date":"2014","source":"Rinsho shinkeigaku = Clinical neurology","url":"https://pubmed.ncbi.nlm.nih.gov/24990830","citation_count":7,"is_preprint":false},{"pmid":"32345222","id":"PMC_32345222","title":"Basic biochemical characterization of cytosolic enzymes in thymidine nucleotide synthesis in adult rat tissues: implications for tissue specific mitochondrial DNA depletion and deoxynucleoside-based therapy for TK2-deficiency.","date":"2020","source":"BMC molecular and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/32345222","citation_count":7,"is_preprint":false},{"pmid":"3494716","id":"PMC_3494716","title":"A novel HLA class II alloantigen detected by an alloantiserum TK2.","date":"1987","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/3494716","citation_count":7,"is_preprint":false},{"pmid":"28812460","id":"PMC_28812460","title":"Myopathic mtDNA Depletion Syndrome Due to Mutation in TK2 Gene.","date":"2017","source":"Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society","url":"https://pubmed.ncbi.nlm.nih.gov/28812460","citation_count":6,"is_preprint":false},{"pmid":"9598140","id":"PMC_9598140","title":"Substrate/inhibitor specificities of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2).","date":"1998","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/9598140","citation_count":5,"is_preprint":false},{"pmid":"27660820","id":"PMC_27660820","title":"Novel TK2 mutations as a cause of delayed muscle maturation in mtDNA depletion syndrome.","date":"2016","source":"Neurology. Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/27660820","citation_count":5,"is_preprint":false},{"pmid":"36232299","id":"PMC_36232299","title":"Pathological Features in Paediatric Patients with TK2 Deficiency.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36232299","citation_count":3,"is_preprint":false},{"pmid":"32904881","id":"PMC_32904881","title":"Mild myopathic phenotype in a patient with homozygous c.416C > T mutation in TK2 gene.","date":"2020","source":"Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology","url":"https://pubmed.ncbi.nlm.nih.gov/32904881","citation_count":3,"is_preprint":false},{"pmid":"40030095","id":"PMC_40030095","title":"Infantile TK2 Deficiency Causing Mitochondrial Encephalomyopathy With Migrating Focal Seizures.","date":"2025","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/40030095","citation_count":3,"is_preprint":false},{"pmid":"34973561","id":"PMC_34973561","title":"Generation of an induced pluripotent stem cell line from a compound heterozygous patient in TK2 gene.","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/34973561","citation_count":1,"is_preprint":false},{"pmid":"41571587","id":"PMC_41571587","title":"Exploring Outcome Measures for Mitochondrial Myopathies; Insights From a Longitudinal Study on TK2 Deficiency.","date":"2026","source":"Journal of inherited metabolic disease","url":"https://pubmed.ncbi.nlm.nih.gov/41571587","citation_count":1,"is_preprint":false},{"pmid":"35280287","id":"PMC_35280287","title":"Case Report: Thymidine Kinase 2 (TK2) Deficiency: A Novel Mutation Associated With Childhood-Onset Mitochondrial Myopathy and Atypical Progression.","date":"2022","source":"Frontiers in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/35280287","citation_count":1,"is_preprint":false},{"pmid":"40967432","id":"PMC_40967432","title":"Compartmentalized thymidine phosphorylation by mitochondrial nucleotide kinases TK2 and CMPK2.","date":"2025","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40967432","citation_count":0,"is_preprint":false},{"pmid":"40098049","id":"PMC_40098049","title":"Novel biallelic TK2 mutations cause mitochondrial DNA depletion syndrome with infantile early-onset lipid storage myopathy.","date":"2025","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/40098049","citation_count":0,"is_preprint":false},{"pmid":"28384473","id":"PMC_28384473","title":"SCA31 Flies Perform in a Balancing Act between RAN Translation and RNA-Binding Proteins.","date":"2017","source":"Neuron","url":"https://pubmed.ncbi.nlm.nih.gov/28384473","citation_count":0,"is_preprint":false},{"pmid":"41500441","id":"PMC_41500441","title":"Tk2 deficiency-mediated mitochondrial dysfunction drives neuroinflammation and seizure frequency in epilepsy.","date":"2026","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/41500441","citation_count":0,"is_preprint":false},{"pmid":"41808087","id":"PMC_41808087","title":"First case of schizophrenia and OCD in TK2-related mitochondrial DNA depletion myopathy: a case report.","date":"2026","source":"BMC psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/41808087","citation_count":0,"is_preprint":false},{"pmid":"41199730","id":"PMC_41199730","title":"National diagnostic gaps for TK2 Deficiency in Italy: insights from the AIM Multicenter Survey.","date":"2025","source":"Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology","url":"https://pubmed.ncbi.nlm.nih.gov/41199730","citation_count":0,"is_preprint":false},{"pmid":"21864241","id":"PMC_21864241","title":"Biochemistry and biology of 2'-Fluoro-2'-deoxythymidine (FT), a putative highly selective substrate for thymidine kinase type 2 (TK2).","date":"2012","source":"Current radiopharmaceuticals","url":"https://pubmed.ncbi.nlm.nih.gov/21864241","citation_count":0,"is_preprint":false},{"pmid":"41771327","id":"PMC_41771327","title":"Late-onset TK2 deficiency in adults: Long-term clinical outcomes of deoxynucleoside therapy.","date":"2026","source":"Mitochondrion","url":"https://pubmed.ncbi.nlm.nih.gov/41771327","citation_count":0,"is_preprint":false},{"pmid":"38502357","id":"PMC_38502357","title":"Creatine kinase elevation in chronic hepatitis B patients with telbivudine therapy: influence of telbivudine plasma concentration and single nucleotide polymorphisms of TK2, RRM2B, and NME4.","date":"2024","source":"European journal of clinical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38502357","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32318,"output_tokens":3709,"usd":0.076295},"stage2":{"model":"claude-opus-4-6","input_tokens":7099,"output_tokens":2685,"usd":0.15393},"total_usd":0.230225,"stage1_batch_id":"msgbatch_01RPbVc9PDH9zQmYK5Hs6srm","stage2_batch_id":"msgbatch_01JVbVLzeKN2yVrsGp3zC8aM","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2002,\n      \"finding\": \"Human TK2 (and Xenopus orthologue Xen-PyK) phosphorylates pyrimidine deoxynucleosides (thymidine and deoxycytidine) following Michaelis-Menten kinetics for deoxycytidine and showing negative cooperativity with thymidine; TK2-like enzymes exist as homodimers and are subject to feedback inhibition by dTTP and dCTP in a complex substrate-dependent pattern, distinguishing them from other deoxyribonucleoside kinase subfamilies.\",\n      \"method\": \"In vitro enzyme kinetics, substrate specificity assays, analytical ultracentrifugation (homodimer determination), feedback inhibition assays with purified recombinant enzymes\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro enzyme kinetics with multiple orthogonal biochemical methods\",\n      \"pmids\": [\"11812127\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TK2 deficiency causes mtDNA depletion and respiratory chain dysfunction selectively in skeletal muscle because this tissue combines low basal TK2 activity with a high requirement for mitochondrially encoded proteins; other tissues (liver, brain, heart, skin) maintain normal mtDNA content and remain unaffected.\",\n      \"method\": \"TK2 enzyme activity assays and mtDNA content measurement in mitochondria isolated from multiple tissues of TK2-deficient patients\",\n      \"journal\": \"Molecular genetics and metabolism\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical measurement across multiple tissues establishing mechanistic basis of tissue specificity\",\n      \"pmids\": [\"12765840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Non-nucleoside tritylated compounds (e.g., KIN-52) are the first selective non-nucleoside inhibitors of TK2, acting as reversible, purely uncompetitive inhibitors with respect to ATP (contrasting with BVDU which is noncompetitive), and competitively with respect to thymidine, without being alternative substrates; molecular modeling places them outside the nucleoside binding pocket.\",\n      \"method\": \"Enzyme inhibition kinetics (IC50, Ki determination), competitive inhibition analysis with respect to thymidine and ATP, computer-assisted molecular modeling\",\n      \"journal\": \"Molecular pharmacology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinetic characterization with mechanistic inhibition analysis and molecular modeling\",\n      \"pmids\": [\"12527796\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Transgenic cardiac overexpression of TK2 (but not cytosolic TK1) in mice doubles mtDNA abundance, increases complex I subunit levels, succinate dehydrogenase activity, and cristae density, demonstrating that TK2 activity is rate-limiting for mitochondrial dNTP supply and mtDNA biogenesis in heart; NRTI treatment abrogates the functional effects of elevated TK2 activity, linking TK2-mediated mitochondrial phosphorylation to NRTI mitochondrial toxicity.\",\n      \"method\": \"Cardiac-specific transgenic mouse overexpression, echocardiography, NMR imaging, TK enzyme activity assays, mtDNA quantification, immunohistochemistry, electron microscopy\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic gain-of-function with multiple orthogonal readouts establishing causal role of TK2 in mtDNA maintenance\",\n      \"pmids\": [\"17322372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FMAU (fluoroarabinofuranosyl thymine) is preferentially phosphorylated by mitochondrial TK2 rather than cytosolic TK1; TK2 inhibition selectively decreases FMAU retention and phosphorylation; FMAU retention correlates with TK2 activity and mitochondrial mass under cellular stress conditions (r²=0.87–0.88), establishing TK2 as the primary kinase for FMAU in mitochondria.\",\n      \"method\": \"Radiotracer retention assays, HPLC metabolite analysis, TK1/TK2 activity assays (FLT/Ara-T phosphorylation), flow cytometry for mitochondrial mass, selective TK2 inhibition\",\n      \"journal\": \"European journal of nuclear medicine and molecular imaging\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct enzyme activity assays, selective inhibition, and multiple correlative methods in cell lines\",\n      \"pmids\": [\"18265975\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In TK2-deficient fibroblasts, upregulation of the human equilibrative nucleoside transporter 1 (hENT1) at both mRNA and protein levels serves as a compensatory mechanism maintaining normal mtDNA levels; siRNA knockdown of hENT1 (but not TK1) induces mtDNA depletion in TK2-deficient cells, establishing hENT1 as a functional bypass for TK2 in mtDNA maintenance.\",\n      \"method\": \"Real-time RT-PCR, western blotting, siRNA knockdown, mtDNA quantification by real-time PCR in patient-derived fibroblasts\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — siRNA epistasis experiment with defined molecular phenotype (mtDNA depletion) in patient-derived cells\",\n      \"pmids\": [\"19265691\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Disease onset and organ specificity in TK2 deficiency are determined by the developmental downregulation of cytosolic TK1: Tk2-knockout mice are normal until postnatal day 8 when Tk1 activity decreases, unmasking Tk2 deficiency and triggering mtDNA depletion in brain and heart. Tk2-deficient heart compensates by downregulating mitochondrial transcription terminator MTERF3 to increase mitochondrial transcript levels relative to mtDNA, maintaining normal mtDNA-encoded protein levels.\",\n      \"method\": \"Tk2 H126N knockin mouse model (Tk2-/-), TK enzyme activity assays across developmental time points, mtDNA quantification, RT-PCR for mitochondrial transcripts and biogenesis regulators, protein quantification\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic knockin mouse model with mechanistic dissection of onset and organ specificity across multiple tissues and timepoints\",\n      \"pmids\": [\"20940150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TK2 phosphorylates deoxycytidine to generate dCTP; siRNA knockdown of TK2 in cancer cells reduces dCTP levels, increases deoxycytidine kinase (dCK) activity, and sensitizes high-TK2-expressing tumor cells (MCF7, HeLa) to gemcitabine by enhancing gemcitabine activation and causing mitochondrial damage (decreased mitochondrial redox status, DNA content, and respiratory activity); knockdown of TK1 or thymidylate synthase does not replicate this effect.\",\n      \"method\": \"siRNA knockdown, cell viability assays, dCTP/dNTP pool measurement, dCK activity assay, mitochondrial function assays (redox status, mtDNA content, complex activity), comparative KD of TK1 and TS\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with multiple orthogonal mechanistic readouts and genetic controls distinguishing TK2 from paralogs\",\n      \"pmids\": [\"26087398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Therapeutic efficacy of deoxycytidine (dCtd) + thymidine (dThd) supplementation in Tk2-deficient mice depends critically on cytosolic pyrimidine salvage enzymes TK1 and dCK, which convert the exogenous deoxynucleosides to monophosphates; temporal and tissue-specific downregulation of TK1 correlates with the onset and organ specificity of disease and with tissue-specific therapeutic response. In human muscle, expression of both TK1 and dCK accounts for long-term therapeutic efficacy of deoxynucleoside therapy.\",\n      \"method\": \"Tk2-/- knockin mouse model, parenteral vs. oral deoxynucleoside dosing, tissue deoxynucleoside bioavailability measurement, TK1/dCK enzyme activity assays, mtDNA quantification across tissues, human muscle expression analysis\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection in mouse model with human tissue validation and multiple orthogonal readouts\",\n      \"pmids\": [\"31383553\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"In adult rat tissues, a cytosolic isoform of TK2 exists with similar substrate specificity to mitochondrial TK2; skeletal muscle mitochondria have the lowest total TK activity of all tissues examined, indicating they are most dependent on both the salvage and de novo synthesis pathways for dTTP, explaining why TK2 deficiency preferentially affects skeletal muscle.\",\n      \"method\": \"Enzyme activity assays in cytosolic and mitochondrial fractions from multiple rat tissues, substrate specificity characterization, thymidylate synthase and p53R2 protein/activity measurement\",\n      \"journal\": \"BMC molecular and cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct biochemical characterization across tissues, single lab study\",\n      \"pmids\": [\"32345222\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"TK2 and CMPK2 (cytidine/uridine monophosphate kinase 2) physically interact in the mitochondrial matrix, forming a functional complex that channels thymidine through two-step phosphorylation (thymidine → TMP → TDP) in a compartmentalized manner; TMP provided exogenously is dephosphorylated to thymidine before salvage by TK2, and this compartmentalization—not transport barriers—accounts for the inability of exogenous TMP to serve as a direct precursor for dTTP synthesis in intact or broken mitochondria from heart, liver, kidney, and brain.\",\n      \"method\": \"Isolated intact and broken mitochondria from rat heart, liver, kidney, and brain; azidothymidine (TK2 inhibitor) blocking experiments; radiolabeled TMP incorporation assays; proximity labeling; immunofluorescence microscopy; differential fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution in isolated mitochondria with inhibitor controls, proximity labeling, and fractionation across multiple tissues\",\n      \"pmids\": [\"40967432\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"Loss of TK2 in brain tissue activates the cGAS-STING innate immune pathway, upregulates inflammatory genes, and increases seizure susceptibility; TK2 expression is inversely correlated with seizure frequency in human epileptogenic brain tissue and is reduced in multiple brain regions in two rodent seizure models, establishing a mechanistic link between TK2-mediated mitochondrial function, mitochondrial DNA-driven inflammation, and neuronal excitability.\",\n      \"method\": \"Proteomic profiling of human epileptogenic brain tissue, pilocarpine and ferric chloride rodent seizure models, Tk2 knockdown/loss-of-function, cGAS-STING pathway gene expression analysis, seizure susceptibility assays\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with pathway-level mechanistic follow-up (cGAS-STING), single lab, human tissue correlation\",\n      \"pmids\": [\"41500441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"N1-substituted thymine derivatives with a hexamethylene spacer competitively inhibit TK2 with respect to thymidine and uncompetitively with respect to ATP (IC50 0.3–0.5 µM), as modeled by docking into a homology-based structure of human TK2, identifying structural determinants of TK2 active site selectivity.\",\n      \"method\": \"Enzyme inhibition kinetics, IC50 determination against TK2/Dm-dNK/HSV-1 TK, competitive inhibition analysis, homology modeling and docking\",\n      \"journal\": \"Journal of medicinal chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro enzyme kinetics with mechanistic inhibition mode determination and structural modeling; single lab\",\n      \"pmids\": [\"17181158\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TK2 is a mitochondrial matrix pyrimidine deoxynucleoside kinase (homodimer) that phosphorylates thymidine and deoxycytidine as the rate-limiting step in the mitochondrial salvage pathway for dNTP supply; its activity is essential for mtDNA maintenance in post-mitotic tissues (especially skeletal muscle, which has the lowest compensatory TK capacity), disease onset in TK2-deficient mice is triggered by developmental downregulation of cytosolic TK1, TK2 physically associates with CMPK2 in the mitochondrial matrix to channel thymidine through compartmentalized two-step phosphorylation, loss of TK2 activates the cGAS-STING inflammatory pathway, and cytosolic salvage enzymes TK1 and dCK are critical determinants of the therapeutic efficacy of deoxynucleoside substrate supplementation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"TK2 is a mitochondrial matrix pyrimidine deoxynucleoside kinase that catalyzes the rate-limiting phosphorylation of thymidine and deoxycytidine in the mitochondrial salvage pathway, thereby sustaining dNTP pools essential for mtDNA replication and maintenance in post-mitotic tissues. TK2 functions as a homodimer subject to feedback inhibition by dTTP and dCTP, displays negative cooperativity with thymidine, and physically associates with CMPK2 in the mitochondrial matrix to channel thymidine through compartmentalized two-step phosphorylation to TDP [PMID:11812127, PMID:40967432]. Tissue-specific vulnerability to TK2 deficiency—most severe in skeletal muscle and brain—is determined by the developmental downregulation of cytosolic TK1, which unmasks the dependence on mitochondrial salvage; compensatory mechanisms including hENT1 upregulation can partially buffer mtDNA depletion in some cell types [PMID:20940150, PMID:12765840, PMID:19265691]. Loss of TK2 in brain activates the cGAS-STING innate immune pathway and increases seizure susceptibility, while therapeutic deoxynucleoside supplementation in TK2 deficiency requires cytosolic TK1 and dCK for conversion of exogenous substrates [PMID:41500441, PMID:31383553].\",\n  \"teleology\": [\n    {\n      \"year\": 2002,\n      \"claim\": \"Establishing TK2's fundamental enzymology—homodimeric architecture, dual pyrimidine substrate specificity, and product feedback inhibition—defined it as a distinct deoxynucleoside kinase subfamily with a unique regulatory logic.\",\n      \"evidence\": \"Purified recombinant enzyme kinetics, analytical ultracentrifugation, and feedback inhibition assays\",\n      \"pmids\": [\"11812127\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of human TK2 was solved\", \"Kinetic parameters under physiological dNTP concentrations were not measured\", \"Regulation by post-translational modifications unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Measurement of TK2 activity across patient tissues revealed that skeletal muscle uniquely combines low basal TK2 activity with high mitochondrial protein demand, explaining the tissue-selective mtDNA depletion in TK2 deficiency.\",\n      \"evidence\": \"TK2 enzyme activity assays and mtDNA quantification in mitochondria from multiple tissues of TK2-deficient patients\",\n      \"pmids\": [\"12765840\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Brain involvement was not fully characterized at this stage\", \"Developmental timing of disease onset not yet explained\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Identification of non-nucleoside uncompetitive TK2 inhibitors demonstrated that the enzyme's active site accommodates non-substrate ligands at a distinct binding mode, opening pharmacological dissection of TK2 function.\",\n      \"evidence\": \"In vitro enzyme inhibition kinetics and molecular modeling with tritylated compounds\",\n      \"pmids\": [\"12527796\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cellular or in vivo validation of inhibitors\", \"Binding site not experimentally resolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Cardiac-specific TK2 overexpression doubled mtDNA abundance and increased respiratory complex levels, proving TK2 is rate-limiting for mitochondrial dNTP supply and mtDNA biogenesis in vivo, and linking TK2-mediated phosphorylation to NRTI mitochondrial toxicity.\",\n      \"evidence\": \"Transgenic mouse overexpression with echocardiography, NMR, mtDNA quantification, and electron microscopy\",\n      \"pmids\": [\"17322372\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether rate-limiting role generalizes to all post-mitotic tissues was untested\", \"Mechanism of NRTI interaction with TK2 substrates not fully dissected\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery that hENT1 upregulation compensates for TK2 loss in fibroblasts—and that hENT1 knockdown unmasks mtDNA depletion—identified nucleoside transport as a bypass route, explaining why some cell types tolerate TK2 deficiency.\",\n      \"evidence\": \"siRNA knockdown of hENT1 and TK1 in patient-derived TK2-deficient fibroblasts with mtDNA quantification\",\n      \"pmids\": [\"19265691\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether hENT1 compensation operates in affected tissues (muscle, brain) in vivo was unknown\", \"Mechanism linking enhanced transport to dNTP synthesis unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"The Tk2 knockin mouse revealed that disease onset at postnatal day 8 is triggered by developmental downregulation of cytosolic TK1, establishing that the timing and organ specificity of TK2-deficiency disease reflect the balance between mitochondrial and cytosolic salvage pathways.\",\n      \"evidence\": \"Tk2 H126N knockin mouse with TK activity assays across developmental timepoints and tissues, mtDNA and transcript quantification\",\n      \"pmids\": [\"20940150\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signals controlling developmental TK1 downregulation not identified\", \"Compensatory MTERF3 mechanism in heart not tested by genetic rescue\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Demonstrating that therapeutic deoxynucleoside supplementation depends on cytosolic TK1 and dCK for substrate activation explained tissue-specific therapeutic efficacy and established the pharmacological bottleneck for TK2-deficiency treatment.\",\n      \"evidence\": \"Tk2-/- mouse model with parenteral and oral deoxynucleoside dosing, tissue bioavailability, enzyme activity assays, and human muscle expression validation\",\n      \"pmids\": [\"31383553\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Optimal dosing regimen and long-term efficacy in patients not established mechanistically\", \"Whether direct mitochondrial nucleotide delivery could bypass cytosolic activation untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Detection of a cytosolic TK2 isoform in rat tissues and confirmation that skeletal muscle mitochondria have the lowest total TK capacity of any tissue reinforced the mechanistic basis for muscle-selective vulnerability.\",\n      \"evidence\": \"Enzyme activity assays in cytosolic and mitochondrial fractions from multiple rat tissues\",\n      \"pmids\": [\"32345222\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cytosolic TK2 isoform not characterized at the molecular level (alternative splicing, protein identity)\", \"Findings from rat tissue not validated in human samples\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Discovery that TK2 physically associates with CMPK2 in the mitochondrial matrix to channel thymidine through compartmentalized two-step phosphorylation resolved why exogenous TMP cannot serve as a direct dTTP precursor—it must be dephosphorylated and re-phosphorylated by the TK2-CMPK2 complex.\",\n      \"evidence\": \"Isolated intact and broken mitochondria from multiple rat tissues, azidothymidine blocking, radiolabeled TMP assays, proximity labeling, immunofluorescence\",\n      \"pmids\": [\"40967432\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and structural basis of TK2-CMPK2 complex not determined\", \"Whether the complex includes additional partners (e.g., NDPK) unknown\", \"Functional significance in human tissues not directly tested\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Linking TK2 loss in brain to cGAS-STING pathway activation and increased seizure susceptibility established a previously unrecognized connection between mitochondrial dNTP salvage, mtDNA-driven innate immunity, and neuronal excitability.\",\n      \"evidence\": \"Proteomic profiling of human epileptogenic brain, rodent seizure models, Tk2 knockdown, cGAS-STING gene expression analysis\",\n      \"pmids\": [\"41500441\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether cGAS-STING activation is caused by mtDNA release or nuclear DNA damage not distinguished\", \"Causal chain from TK2 loss to seizure phenotype not fully delineated\", \"Single-lab finding awaiting independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A high-resolution structure of the human TK2-CMPK2 complex, the identity and regulation of the putative cytosolic TK2 isoform, and the precise mechanism by which TK2 deficiency triggers cGAS-STING activation remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No crystal or cryo-EM structure of human TK2 or TK2-CMPK2 complex\", \"Molecular identity of cytosolic TK2 isoform undetermined\", \"Specific mtDNA species or damage signals activating cGAS-STING downstream of TK2 loss not identified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 3, 4, 7]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [1, 3, 10]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 3, 7, 10]},\n      {\"term_id\": \"R-HSA-69306\", \"supporting_discovery_ids\": [3, 6]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [11]}\n    ],\n    \"complexes\": [\n      \"TK2-CMPK2 mitochondrial matrix complex\"\n    ],\n    \"partners\": [\n      \"CMPK2\",\n      \"SLC29A1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}